Abstract
Purpose :
Purpose: To investigate 2-year visual and anatomic outcomes of eyes with intravitreal aflibercept injection according to fixed 2 month interval for neovascular age-related macular degeneration (nAMD).
Methods :
Methods: Retrospective, single-practice data analysis from a medical record system. A total of 12 eyes (12 patients) with treatment-naive nAMD receiving aflibercept every-2-months for 2 years were reviewed. The primary study outcome was VA in decimal notation converted to minimal angle of resolution scores, and the secondary outcomes were optical coherence tomography (OCT) findings including: central retinal thickness (CRT) and subretinal/intraretinal fluid (SRF/IRF)
Results :
Results: Mean age of patients was 71.2 years (median: 71.5, min: 55, max 86) at baseline. Occult with no classic CNV was 3 eyes (25%), predominantly classic lesions was 5 eyes (42%), and indocyanine-green angiography revealed polypoidal choroidal vasculopathy was 4 eyes (33%). Mean VA was 0.73 at baseline, 0.58 at 3 months, 0.58 at 6 months, 0.55 at 1 year, and 0.40 at 2 years (P < .05). CRT decreased from 322.3 μm at baseline to 282.8 μm at 3 months, 298.9 μm at 6 months, 248.3 μm at 1 year, and 261.8 μm at 2 years (P < .01). At 2 years, 7 eyes (58%) were considered as inactive by absence of intraretinal or subretinal fluid on OCT, however 5 eyes (42%) remained active with the presence of SRF, IRF, intraretinal cysts, or macular haemorrhage. Mean VA at 2 years in the active and inactive groups were 0.52 and 0.31, respectively (P = .59). Mean CRT at 2 years in the active and inactive groups were 321.8 μm and 290.0 μm (P = .14).
Conclusions :
Conclusions: Intravitreal aflibercept administration with fixed 2 month interval for 2 years improved both visual acuity and macular morphology, although number of eyes with nAMD investigated in the present study was small. In addition, eyes with active lesions at 2 years do not have worse visual acuity compared with those with inactive lesions.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.